CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorPINHEIRO, Celine
dc.contributor.authorLONGATTO-FILHO, Adhemar
dc.contributor.authorSOARES, Tony R.
dc.contributor.authorPEREIRA, Helena
dc.contributor.authorBEDROSSIAN, Carlos
dc.contributor.authorMICHAEL, Claire
dc.contributor.authorSCHMITT, Fernando C.
dc.contributor.authorBALTAZAR, Fatima
dc.date.accessioned2013-07-30T17:53:39Z
dc.date.available2013-07-30T17:53:39Z
dc.date.issued2012
dc.description.abstractMalignant mesothelioma (MM) is a rare form of cancer. Its histopathological diagnosis is very difficult, as it exhibits a number of different appearances that can be misinterpreted as metastatic invasion or atypical hyperplasia. Thus, there is an urgent need to identify adequate markers to distinguish between benign and malignant cells, allowing the implementation of appropriate therapies and, possibly, specific directed therapies. MM, like other tumors, show an increase in glucose uptake, due to high rates of glycolysis, inducing an intracellular overload of acids. In this context, monocarboxylate transporters (MCTs) emerge as important players, by mediating the transmembranar co-transport of lactate with a proton, thereby, regulating pH and allowing continuous glycolysis. Importantly, proper MCT expression and activity depend on its co-expression with a chaperone, CD147, which is associated with poor prognosis in cancer. Twenty-two samples including reactive mesothelial cells, MM, and atypical mesothelial hyperplasias were evaluated for immunoexpression of MCT1, MCT4, and CD147. Expression of these proteins was compared with GLUT1 as a new promising marker for MM. Although MCT isoforms were not differentially expressed in the two types of cytological specimens, CD147, as GLUT1, was almost exclusively expressed in MM. Both MCT1 and MCT4 are not able to discriminate between mesothelial reactive cells and mesothelial malignant cells, while CD147 was able to distinguish these two proliferations. If confirmed, besides being a good marker for identification of MM, CD147 may also be a target for therapeutical strategies in this rare type of tumor. Diagn. Cytopathol. 2012;40:478483. (c) 2012 Wiley Periodicals, Inc.
dc.description.indexMEDLINE
dc.description.sponsorshipFCT (Portuguese Foundation for Science and Technology) [SFRH/BPD/69479/2010]
dc.identifier.citationDIAGNOSTIC CYTOPATHOLOGY, v.40, n.6, Special Issue, p.478-483, 2012
dc.identifier.doi10.1002/dc.22821
dc.identifier.issn8755-1039
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1585
dc.language.isoeng
dc.publisherWILEY-BLACKWELL
dc.relation.ispartofDiagnostic Cytopathology
dc.rightsrestrictedAccess
dc.rights.holderCopyright WILEY-BLACKWELL
dc.subjectmonocarboxylate transporters
dc.subjectCD147
dc.subjectEMMPRIN
dc.subjectmalignant mesothelioma
dc.subject.otherpositron-emission-tomography
dc.subject.othermonocarboxylate transporter 1
dc.subject.otherpleural mesothelioma
dc.subject.othercervical-carcinoma
dc.subject.othergene-therapy
dc.subject.otherlactate
dc.subject.otherexpression
dc.subject.otherdiseases
dc.subject.othermetastases
dc.subject.othereffusions
dc.subject.wosMedical Laboratory Technology
dc.subject.wosPathology
dc.titleCD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryPortugal
hcfmusp.affiliation.countryisopt
hcfmusp.affiliation.countryisous
hcfmusp.author.externalPINHEIRO, Celine:Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst, P-4710057 Braga, Portugal; ICVS 3Bs PT Govt Associate Lab, Braga, Portugal
hcfmusp.author.externalSOARES, Tony R.:Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst, P-4710057 Braga, Portugal; ICVS 3Bs PT Govt Associate Lab, Braga, Portugal
hcfmusp.author.externalPEREIRA, Helena:Univ Minho, Ctr Mol & Environm Biol, P-4710057 Braga, Portugal
hcfmusp.author.externalBEDROSSIAN, Carlos:Rush Univ, Dept Pathol, Coll Med, Chicago, IL 60612 USA
hcfmusp.author.externalMICHAEL, Claire:Univ Michigan, Dept Cytopathol, Ann Arbor, MI 48109 USA
hcfmusp.author.externalSCHMITT, Fernando C.:Univ Porto, Fac Med, P-4100 Oporto, Portugal; Univ Porto, Inst Mol Pathol & Immunol, P-4100 Oporto, Portugal
hcfmusp.author.externalBALTAZAR, Fatima:Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst, P-4710057 Braga, Portugal; ICVS 3Bs PT Govt Associate Lab, Braga, Portugal
hcfmusp.citation.scopus29
hcfmusp.contributor.author-fmusphcADHEMAR LONGATTO FILHO
hcfmusp.description.beginpage478
hcfmusp.description.endpage483
hcfmusp.description.issue6
hcfmusp.description.issueSpecial Issue
hcfmusp.description.volume40
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed22619123
hcfmusp.origem.scopus2-s2.0-84861540266
hcfmusp.origem.wosWOS:000304303200003
hcfmusp.publisher.cityHOBOKEN
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceBEDROSSIAN CWM, 1992, SEMIN DIAGN PATHOL, V9, P91
hcfmusp.relation.referenceBedrossian CWM, 1998, DIAGN CYTOPATHOL, V19, P131, DOI 10.1002/(SICI)1097-0339(199808)19:2<131::AID-DC14>3.0.CO;2-G
hcfmusp.relation.referenceBedrossian CWM, 1998, DIAGN CYTOPATHOL, V18, P141, DOI 10.1002/(SICI)1097-0339(199802)18:2<141::AID-DC11>3.0.CO;2-L
hcfmusp.relation.referenceBenard F, 1998, CHEST, V114, P713, DOI 10.1378/chest.114.3.713
hcfmusp.relation.referenceBertino P, 2009, EXPERT OPIN PHARMACO, V10, P99, DOI [10.1517/14656560802631285 , 10.1517/14656560802631285]
hcfmusp.relation.referenceBougatef F, 2009, BLOOD, V114, P5547, DOI 10.1182/blood-2009-04-217380
hcfmusp.relation.referenceBrizel DM, 2001, INT J RADIAT ONCOL, V51, P349, DOI 10.1016/S0360-3016(01)01630-3
hcfmusp.relation.referenceBury T, 1997, THORAX, V52, P187
hcfmusp.relation.referenceCarretta A, 2000, EUR J CARDIO-THORAC, V17, P377, DOI 10.1016/S1010-7940(00)00377-8
hcfmusp.relation.referenceCeresoli GL, 2006, J CLIN ONCOL, V24, P4587, DOI 10.1200/JCO.2006.06.8999
hcfmusp.relation.referenceDavidson B, 2004, CLIN EXP METASTAS, V21, P469, DOI 10.1007/s10585-004-3150-2
hcfmusp.relation.referenceFilho AL, 2007, DIAGN CYTOPATHOL, V35, P786, DOI 10.1002/dc.20767
hcfmusp.relation.referenceGrondin SC, 1999, ONCOLOGY-NY, V13, P919
hcfmusp.relation.referenceHasteh F, 2010, CANCER CYTOPATHOL, V118, P90, DOI 10.1002/cncy.20071
hcfmusp.relation.referenceKato Y, 2007, MODERN PATHOL, V20, P215, DOI 10.1038/modpathol.3800732
hcfmusp.relation.referenceKennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI [10.2217/fon.09.145, 10.2217/FON.09.145]
hcfmusp.relation.referenceLumb PD, 2004, HISTOPATHOLOGY, V44, P345, DOI 10.1111/j.1365-2559.2004.01844.x
hcfmusp.relation.referenceLyons-Boudreaux V, 2008, ARCH PATHOL LAB MED, V132, P23, DOI 10.1043/1543-2165(2008)132[23:CMVBHU]2.0.CO;2
hcfmusp.relation.referenceNowak AK, 2002, SEMIN ONCOL, V29, P82, DOI 10.1053/sonc.2002.30234
hcfmusp.relation.referencePasello G, 2009, CURR DRUG TARGETS, V10, P1235
hcfmusp.relation.referencePinheiro C, 2009, EUR J CANCER, V45, P2418, DOI 10.1016/j.ejca.2009.06.018
hcfmusp.relation.referencePinheiro C, 2008, VIRCHOWS ARCH, V452, P139, DOI 10.1007/s00428-007-0558-5
hcfmusp.relation.referencePinheiro C, 2009, DIS MARKERS, V26, P97, DOI 10.3233/DMA-2009-0596
hcfmusp.relation.referencePinheiro C, 2008, INT J GYNECOL PATHOL, V27, P568, DOI 10.1097/PGP.0b013e31817b5b40
hcfmusp.relation.referencePinheiro C, 2010, HISTOPATHOLOGY, V56, P860, DOI 10.1111/j.1365-2559.2010.03560.x
hcfmusp.relation.referenceQuennet V, 2006, RADIOTHER ONCOL, V81, P130, DOI 10.1016/j.radonc.2006.08.012
hcfmusp.relation.referenceRay M, 2009, CHEST, V136, P888, DOI 10.1378/chest.08-2665
hcfmusp.relation.referenceScurry J, 1999, J CLIN PATHOL, V52, P535
hcfmusp.relation.referenceShen J, 2009, AM J CLIN PATHOL, V131, P516, DOI 10.1309/AJCPWFW7O1FVFLKT
hcfmusp.relation.referenceSugarbaker David J, 2010, Expert Rev Respir Med, V4, P363, DOI 10.1586/ers.10.35
hcfmusp.relation.referencevan der Most RG, 2006, CANCER GENE THER, V13, P897, DOI 10.1038/sj.cgt.7700935
hcfmusp.relation.referenceWalenta S, 2000, CANCER RES, V60, P916
hcfmusp.relation.referenceYan TD, 2009, J CLIN ONCOL, V27, P6237, DOI 10.1200/JCO.2009.23.9640
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication4401f59e-efe8-4a24-9f39-0b6bde3c72b7
relation.isAuthorOfPublication.latestForDiscovery4401f59e-efe8-4a24-9f39-0b6bde3c72b7
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_LONGATTO-FILHO_CD147_immunohistochemistry_discriminates_between_reactive_mesothelial_cells_and_2012.PDF
Tamanho:
319.62 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - LIM/14